Executive takeaways
Fund III closed at $82.048M (oversubscribed) and is positioned as a lead pre-seed / seed vehicle writing $500K–$3M checks, with a stated focus on Vertical AI, Deep Tech, Healthcare, and Biotech, primarily in NYC and Boston.
The firm has built a differentiated “speed + founder experience” posture via Pre-Seed Fast Track (commitment to “money in the bank” within 10 business days for eligible pre-seed rounds, typically $250K–$750K checks) and claims strong founder satisfaction (NPS).
While Fund III is new, the franchise has multiple prior vintages (Fund I: $27M; Fund II: $67M) and can point to meaningful outcomes in the broader platform—e.g., Aerodome’s acquisition by Flock Safety and Alkami’s agreement to acquire MANTL for $400M EV.
The most important LP diligence items, given the broader sector mandate (software + health/bio) and larger fund size, are: (1) net performance by vintage, (2) ownership + reserve policy, (3) ability to lead and maintain pro-rata in later rounds, and (4) team bandwidth/specialization across bio/health vs. software.
